| Item Type | Name |
|
Academic Article
|
Heterogeneity in lineage derivation of Philadelphia-positive acute lymphoblastic leukemia expressing p190BCR-ABL or p210BCR-ABL: determination by analysis of individual colonies with the polymerase chain reaction.
|
|
Academic Article
|
Both cell fusion and transdifferentiation account for the transformation of human peripheral blood CD34-positive cells into cardiomyocytes in vivo.
|
|
Concept
|
Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative
|
|
Concept
|
Proto-Oncogene Proteins c-bcr
|
|
Concept
|
CD8-Positive T-Lymphocytes
|
|
Concept
|
Genes, abl
|
|
Concept
|
CD4-Positive T-Lymphocytes
|
|
Concept
|
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
|
|
Concept
|
False Positive Reactions
|
|
Concept
|
Fusion Proteins, bcr-abl
|
|
Concept
|
Leukemia, Myeloid, Chronic-Phase
|
|
Academic Article
|
AMN107, a novel aminopyrimidine inhibitor of p190 Bcr-Abl activation and of in vitro proliferation of Philadelphia-positive acute lymphoblastic leukemia cells.
|
|
Academic Article
|
Central role of tumour necrosis factor, GM-CSF, and interleukin 1 in the pathogenesis of juvenile chronic myelogenous leukaemia.
|
|
Academic Article
|
Synergistic antiproliferative effect of interferon alpha and azidothymidine in chronic myelogenous leukemia.
|
|
Academic Article
|
Juvenile chronic myelogenous leukemia.
|
|
Academic Article
|
B-lineage lymphoid blast crisis in juvenile chronic myelogenous leukemia: II. Interleukin-1-mediated autocrine growth regulation of the lymphoblasts.
|
|
Academic Article
|
The effect of growth hormone and IGF-I on clonogenic growth of hematopoietic cells in leukemic patients during active disease and during remission--a preliminary report.
|
|
Academic Article
|
Z-138: a new mature B-cell acute lymphoblastic leukemia cell line from a patient with transformed chronic lymphocytic leukemia.
|
|
Academic Article
|
Detection of residual disease in acute lymphoblastic leukemia of childhood.
|
|
Academic Article
|
The biology of chronic myeloid leukemia.
|
|
Academic Article
|
Monitoring of residual disease in chronic myelogenous leukemia by quantitative polymerase chain reaction and clinical decision making.
|
|
Academic Article
|
Impact of p210(Bcr-Abl) on ultraviolet C wavelength-induced DNA damage and repair.
|
|
Academic Article
|
Survival outcomes for clonal evolution in chronic myeloid leukemia patients on second generation tyrosine kinase inhibitor therapy.
|
|
Academic Article
|
The synthetic heat shock protein 90 (Hsp90) inhibitor EC141 induces degradation of Bcr-Abl p190 protein and apoptosis of Ph-positive acute lymphoblastic leukemia cells.
|
|
Academic Article
|
Treatment with lenalidomide modulates T-cell immunophenotype and cytokine production in patients with chronic lymphocytic leukemia.
|
|
Academic Article
|
Small molecule ErbB inhibitors decrease proliferative signaling and promote apoptosis in philadelphia chromosome-positive acute lymphoblastic leukemia.
|
|
Academic Article
|
Recombinant human interferon alpha-2 and juvenile chronic myelogenous leukemia: cell receptor binding, enzymatic induction, and growth suppression in vitro.
|
|
Academic Article
|
Juvenile chronic myelogenous leukemia: characterization of the disease using cell cultures.
|
|
Academic Article
|
Cytokines and their antagonists in myeloid disorders.
|
|
Academic Article
|
Altered levels of interleukin-1 beta and interleukin-1 receptor antagonist in chronic myelogenous leukemia: clinical and prognostic correlates.
|
|
Academic Article
|
CML: mechanisms of disease initiation and progression.
|
|
Academic Article
|
Molecular and biologic characterization of a newly established Philadelphia-positive acute lymphoblastic leukemia cell line (Z-33) with an autocrine response to GM-CSF.
|
|
Academic Article
|
Identification of human juvenile chronic myelogenous leukemia stem cells capable of initiating the disease in primary and secondary SCID mice.
|
|
Academic Article
|
Conversion of interferon-induced, long-term cytogenetic remissions in chronic myelogenous leukemia to polymerase chain reaction negativity.
|
|
Academic Article
|
Should polymerase chain reaction analysis to detect minimal residual disease in patients with chronic myelogenous leukemia be used in clinical decision making?
|
|
Academic Article
|
Polymerase chain reaction analyses should be used as a basis for clinical decision making in patients with chronic myelogenous leukemia.
|
|
Academic Article
|
Outcome of Philadelphia chromosome-positive adult acute lymphoblastic leukemia.
|
|
Academic Article
|
Clinical significance of minimal residual disease in leukemia.
|
|
Academic Article
|
Expression of apoptosis proteins in chronic myelogenous leukemia: associations and significance.
|
|
Academic Article
|
Reduced focal adhesion kinase and paxillin phosphorylation in BCR-ABL-transfected cells.
|
|
Academic Article
|
Distinct biological impact of dephosphorylation vs. downregulation of p210Bcr-Abl: implications for imatinib mesylate response and resistance.
|
|
Academic Article
|
Circulating heat shock protein 70 and progression in patients with chronic myeloid leukemia.
|
|
Academic Article
|
Differentiation in B-precursor acute lymphoblastic leukemia cell populations with CD34-positive subpopulations.
|
|
Academic Article
|
Suppression of chronic myelogenous leukemia colony growth by interleukin-1 (IL-1) receptor antagonist and soluble IL-1 receptors: a novel application for inhibitors of IL-1 activity.
|
|
Academic Article
|
The value of intensive combination chemotherapy for juvenile chronic myelogenous leukemia.
|
|
Academic Article
|
[Recent advances in juvenile chronic myelogenous leukemia].
|
|
Academic Article
|
Characterization of malignant peripheral blood cells of juvenile chronic myelogenous leukemia.
|
|
Academic Article
|
Residual juvenile chronic myelogenous leukemia cells detected in peripheral blood during clinical remission.
|
|
Academic Article
|
Interruption of autocrine and paracrine growth-stimulatory mechanisms: a new therapeutic strategy for chronic myelogenous leukemia.
|
|
Academic Article
|
Chronic myelogenous leukemia: a concise update.
|
|
Academic Article
|
Selective inhibition of cell proliferation and BCR-ABL phosphorylation in acute lymphoblastic leukemia cells expressing Mr 190,000 BCR-ABL protein by a tyrosine kinase inhibitor (CGP-57148).
|
|
Academic Article
|
Chronic myelogenous leukemia: biology and therapy.
|
|
Academic Article
|
Cell-penetrating SH3 domain blocker peptides inhibit proliferation of primary blast cells from CML patients.
|
|
Academic Article
|
Studies of minimal residual disease in acute lymphocytic leukemia.
|
|
Academic Article
|
Expression of a truncated first exon BCR sequence in chronic myelogenous leukemia cells blocks cell growth and induces cell death.
|
|
Academic Article
|
Adaphostin-induced oxidative stress overcomes BCR/ABL mutation-dependent and -independent imatinib resistance.
|
|
Academic Article
|
Activation of a novel Bcr/Abl destruction pathway by WP1130 induces apoptosis of chronic myelogenous leukemia cells.
|
|
Academic Article
|
The use of nilotinib or dasatinib after failure to 2 prior tyrosine kinase inhibitors: long-term follow-up.
|
|
Academic Article
|
Epstein-Barr virus-induced CD30-positive diffuse large B-cell lymphoma in a patient with mixed-phenotypic leukemia treated with clofarabine.
|
|
Academic Article
|
Detection of dormant chronic myeloid leukemia clones in the bone marrow of patients in complete molecular remission.
|
|
Academic Article
|
Chronic myeloid leukemia following radiotherapy for breast cancer.
|
|
Academic Article
|
Persistence of dormant leukemic progenitors during interferon-induced remission in chronic myelogenous leukemia. Analysis by polymerase chain reaction of individual colonies.
|
|
Academic Article
|
Leukemia inhibitory factor in long-term adherent layer cultures: increased levels of bioactive protein in leukemia and modulation by IL-4, IL-1 beta, and TNF-alpha.
|
|
Academic Article
|
Ubiquitous expression of cytokines in diverse leukemias of lymphoid and myeloid lineage.
|
|
Academic Article
|
Suppression of chronic myelogenous leukemia colony growth by interleukin-4.
|
|
Academic Article
|
Phase I/II study of subcutaneous homoharringtonine in patients with chronic myeloid leukemia who have failed prior therapy.
|
|
Academic Article
|
Detection of MRD may predict the outcome of patients with Philadelphia chromosome-positive ALL treated with tyrosine kinase inhibitors plus chemotherapy.
|
|
Academic Article
|
Role of interleukin-1 inhibitory molecules in therapy of acute and chronic myelogenous leukemia.
|
|
Academic Article
|
Role of granulocyte-macrophage colony-stimulating factor in Philadelphia (Ph1)-positive acute lymphoblastic leukemia: studies on two newly established Ph1-positive acute lymphoblastic leukemia cell lines (Z-119 and Z-181).
|
|
Academic Article
|
Carcinoma of the stomach metastatic to the liver that progressed after hepatic arterial infusion of cisplatin plus 5-floxuridine, and then dramatically regressed after chemoembolization based on positive chromogranin staining.
|
|
Academic Article
|
Expression of constitutively active nuclear-kappa B RelA transcription factor in blasts of acute myeloid leukemia.
|
|
Academic Article
|
Isolated mesenteric CD20-positive myeloid sarcoma.
|
|
Academic Article
|
Association of lymphoid malignancies and Philadelphia-chromosome negative myeloproliferative neoplasms: Clinical characteristics, therapy and outcome.
|
|
Academic Article
|
Long-term follow-up of a phase 2 study of chemotherapy plus dasatinib for the initial treatment of patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.
|
|
Academic Article
|
Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: a single-centre, phase 2 study.
|
|
Academic Article
|
Relapsed refractory BRAF-negative, IGHV4-34-positive variant of hairy cell leukemia
|
|
Academic Article
|
Long-term follow-up of a phase 2 study of chemotherapy plus dasatinib for the initial treatment of patients with Philadelphia chromosome-positive acute lymphoblastic leukemia
|
|
Academic Article
|
Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia
|
|
Academic Article
|
Impact of BCR-ABL transcript type on outcome in patients with chronic-phase CML treated with tyrosine kinase inhibitors
|
|
Academic Article
|
Philadelphia-positive dimorphic blasts in mixed-phenotype acute leukemia with TET2 mutation
|
|
Academic Article
|
Relapsed Refractory BRAF-Negative, IGHV4-34-Positive Variant of Hairy Cell Leukemia: A Distinct Entity?
|
|
Academic Article
|
Impact of BCR-ABL transcript type on outcome in patients with chronic-phase CML treated with tyrosine kinase inhibitors.
|
|
Academic Article
|
Philadelphia-positive dimorphic blasts in mixed-phenotype acute leukemia with TET2 mutation.
|
|
Academic Article
|
Ibrutinib Therapy Increases T Cell Repertoire Diversity in Patients with Chronic Lymphocytic Leukemia.
|
|
Academic Article
|
PET-positive lymphadenopathy in CLL-Not always Richter transformation.
|
|
Academic Article
|
Chronic myeloid leukemia among patients with a history of prior malignancies: A tale of dual survivorship.
|
|
Academic Article
|
Phase II trial of homoharringtonine with imatinib in chronic, accelerated, and blast phase chronic myeloid leukemia.
|
|
Academic Article
|
TP53 mutation does not confer a poor outcome in adult patients with acute lymphoblastic leukemia who are treated with frontline hyper-CVAD-based regimens.
|
|
Academic Article
|
Prognostic factors and survival outcomes in patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era: Cohort study of 477 patients.
|
|
Academic Article
|
Ibrutinib modulates the immunosuppressive CLL microenvironment through STAT3-mediated suppression of regulatory B-cell function and inhibition of the PD-1/PD-L1 pathway.
|
|
Academic Article
|
The absolute percent deviation of IGHV mutation rather than a 98% cut-off predicts survival of chronic lymphocytic leukaemia patients treated with fludarabine, cyclophosphamide and rituximab.
|
|
Academic Article
|
Early results of lower dose dasatinib (50?mg daily) as frontline therapy for newly diagnosed chronic-phase chronic myeloid leukemia.
|
|
Academic Article
|
Phase I study of ruxolitinib in previously treated patients with low or intermediate-1 risk myelodysplastic syndrome with evidence of NF-kB activation.
|
|
Academic Article
|
A prospective analysis of symptom burden for patients with chronic myeloid leukemia in chronic phase treated with frontline second- and third-generation tyrosine kinase inhibitors.
|
|
Academic Article
|
Analysis of cardiovascular and arteriothrombotic adverse events in chronic-phase CML patients after frontline TKIs.
|
|
Academic Article
|
Efficacy and safety of generic imatinib after switching from original imatinib in patients treated for chronic myeloid leukemia in the United States.
|
|
Academic Article
|
Long-term follow-up of lower dose dasatinib (50?mg daily) as frontline therapy in newly diagnosed chronic-phase chronic myeloid leukemia.
|
|
Academic Article
|
Long-term results of frontline dasatinib in chronic myeloid leukemia.
|
|
Academic Article
|
Long-term results of a phase 2 trial of nilotinib 400?mg twice daily in newly diagnosed patients with chronic-phase chronic myeloid leukemia.
|
|
Academic Article
|
Phase I/II study of dasatinib in combination with decitabine in patients with accelerated or blast phase chronic myeloid leukemia.
|
|
Academic Article
|
Altered T-cell subset repertoire affects treatment outcome of patients with myelofibrosis.
|
|
Academic Article
|
Clinicopathologic correlates and natural history of atypical chronic myeloid leukemia.
|